FSCN1 and thymoma: In particular, Sato and colleagues reported a positive correlation between the number of fascin+ DCs and a favorable outcome for thymoma patients, and also demonstrated a paucity of DCs in TCs, overall indicating that DCs can activate anti-tumor immunity to suppress tumor growth and invasiveness (93).